II. To determine the progression-free survival (PFS), pathCR rate, time to relapse (TTR), disease-free survival (DFS), R0 rate, and overall survival (OS) of pembrolizumab when combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX) chemotherapy. (only if Phase Ib is re-initiated)